Extrait

This observational study will assess the safety of Herceptin (trastuzumab) in patients with HER2-positive breast cancer in routine clinical practice. Eligible patients will be followed for up to 4 years.

Critère d'inclusion

• Breast Cancer

Liens

• ictrp
• nct